ATOSSA THERAPEUTICS, INC. 8-KCurrent Reports (8-K / ad hoc)

Financial Statements

Item 8.01 Other Events. On September 29, 2026, Atossa Therapeutics, Inc. (the “Company”) announced that its board of directors has approved a plan to issue one contingent value right to each share of the Company’s common stock to enable stockholders to share in a portion of any proceeds received from the monetization of the Company’s first qualifying rare pediatric disease priority review voucher. A copy of the related press release is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.